PTK Banner

New screening technologies, in vitro assays and in vivo models continue to be developed, but is the right tool being used at the right time to predict and detect adverse events? Cambridge Healthtech Institute’s eighth annual conference on New Models for Predicting Drug Toxicity, looks at the scientific and technological progress being made to better predict drug-related toxicities at the preclinical stage, and avoid costly mistakes in the clinic.

Preliminary Agenda | Speaker Biographies 


EFFECTIVE USE OF IN VITRO AND IN VIVO MODELS 

KEYNOTE PRESENTATION: Mice with ‘Humanized’ Livers: From Safer Drugs to Liver Regeneration

Gary PeltzGary Peltz, M.D., Ph.D., Professor, Anesthesia, Stanford University





Assay Platforms for Toxicity Evaluation in Small Molecules and Nanomaterials

Robert Damoiseaux, Ph.D., Scientific Director, Molecular Screening Shared Resource California Nanosystems Institute, University of California, Los Angeles

Current Use of Stem Cell-Derived Cardiomyocytes to Assess QT Prolongation and Proarrhythmia

Bernard Fermini, Ph.D., Associate Research Fellow, Global Safety Pharmacology, Pfizer Global Research & Development

How Useful Are in vitro Tools to Predict Hyperbilirubinemia: Utility of UGT1A1, OATP1B1, OATP1B3, MRP2 and BSEP Inhibition Assays

Jae Chang, Ph.D., Senior Scientist, DMPK, Genentech

Proteomic Approaches to the Discovery of Preclinical Biomarkers of Toxicity

Li-Rong Yu, Ph.D., Associate Co-Director, Biomarkers and Alternative Models Branch Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration


EXPLORING ENGINEERED MODELS  

Body-on-a-Chip Devices for Drug Testing: Opportunities and Limitations

Michael Shuler, Ph.D., Samuel B. Eckert Professor of Chemical Engineering and James and Marsha McCormick Chair of Biomedical Engineering, Cornell University

Tissue Chips for Drug Discovery and Screening

Kristin Fabre, Ph.D., Scientific Program Manager, Tissue Chip for Drug Screening Program, National Center for Advancing Translational Sciences (NCATS), NIH

Human Contractile Engineered Muscle for Drug and Toxicity Studies

Nenad Bursac, Ph.D., Rooney Family Associate Professor, Department of Biomedical Engineering, Duke University

Towards Organoid Microarrays for Pan-Hindbrain and Spinal Cord Screening

Krishanu Saha, Ph.D., Assistant Professor, Department of Biomedical Engineering and Bioethics, University of Wisconsin-Madison


PREDICTIVITY OF COMPUTATIONAL TOOLS 

Enhanced Prediction of Drug-Induced Liver Injury by the Development of Liver Toxicity Knowledge Base

Minjun Chen, Ph.D., Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration

An in silico Approach to Predict Intrinsic in vitro Cytotoxicity for Compounds in Primary Human Hepatocytes

BinQing Wei, Ph.D., Scientist, Discovery Chemistry, Genentech

Bioinformatic and Cheminformatic Approaches to Assess Cardiac Arrhythmias

Siobhan Malany, Ph.D., Chemical Biology Team Leader, Chemical Genomics Center, Sanford Burnham Medical Research Institute


For questions or suggestions about the meeting, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
T: (+1) 973-525-4667
E: tkoppal@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com 

WPC 

Prelim Agenda  


Arrow Event At A Glance 


Arrow 2014 Final Brochure 


Arrow View All Sponsors 


Arrow View All Media Partners 


SPONSORSHIPS & EXHIBITS

The exhibit hall has sold out the past four years, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Joseph Vacca
Associate Director, Business Development
781-972-5431
jvacca@healthtech.com 

 

 

Testimonials

WPC Quotes